Refine by
Autoimmune Condition Articles & Analysis
19 news found
Rani Therapeutics Holdings, Inc. recently announced the development of a high-capacity oral biologics device known as the RaniPill HC (High Capacity), capable of delivering up to a 500%-plus higher drug payload than Rani’s existing oral biologics capsule. In preclinical testing, RaniPill HC demonstrated successful delivery of adalimumab and achieved high bioavailability. “The ...
Two novel targets identified through the existing collaboration have already been added to AstraZeneca’s portfolio London, 13 January 2021, BenevolentAI, a leading clinical-stage AI drug discovery company, has expanded its AI-driven drug discovery collaboration with AstraZeneca, doubling the number of disease areas being explored through the partnership. The three-year expansion includes ...
Recent journal publications are fortifying the clinically important role of the 14-3-3η blood test along the whole continuum of RA and autoimmune patient care. From RA meta-analysis data through to 14-3-3η expression in juvenile idiopathic arthritis and secondary Sjögren’s syndrome in Lupus, the importance of this protein across a spectrum of autoimmune conditions is ...
SetPoint Medical, a clinical-stage bioelectronic medicine company developing therapies for chronic autoimmune diseases, today announced the appointment of Amy Derosier as Vice President of Clinical Affairs. “Amy’s extensive experience in successfully designing and executing clinical trials for novel medical devices complements that of our CMO, Dr. David Chernoff, who has extensive ...
Runway Growth Capital LLC (“Runway”), a leading provider of growth loans to both venture and non-venture backed companies seeking an alternative to raising equity, today announced the close of a senior secured term loan of $35 million to SetPoint Medical (“SetPoint”), a Valencia, California based, privately-held clinical-stage bioelectronic medicine company developing ...
Evolve BioSystems, Inc. today announces that its product, activated B. infantis EVC001, will be used in one of the largest international clinical studies on preventing type 1 diabetes (T1D) in genetically predisposed children. The randomized, controlled, double-blind, multicenter trial will be conducted across eight major research centers in five European countries. The Leona M. and Harry B. ...
SetPoint Medical, a clinical-stage bioelectronic medicine company developing therapy for chronic autoimmune diseases, today announced that the American Institute for Biological and Medical Engineering (AIMBE) has elected Murthy Simhambhatla, PhD, to the AIMBE College of Fellows for “outstanding contributions as a medical technology innovator and business leader, advancing health for ...
SetPoint Medical, Inc. today announced that it has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for the use of its novel bioelectronic device for patients with rheumatoid arthritis (RA) who have incomplete response to, or are intolerant to multiple biologic drugs. The Company is developing its platform for the treatment of chronic, ...
Do you have a patient with Systemic Lupus Erythematosus (SLE) that you suspect may also have Sjögren’s Syndrome (SS)? With shared clinical and serological features, overlapping SS with SLE is a comorbidity that is often challenging to identify to promptly assist clinical management. This may also lead to misdiagnoses of other connective tissue disorders. New data on 14-3-3η (eta) ...
Device reduced disease activity in 50% of patients who had failed multiple drug classes including Janus Kinase Inhibitors (JAKi) SetPoint Medical, Inc. today announced that data from a first-in-human pilot trial that evaluated its proprietary Vagus Nerve Stimulation (VNS) microregulator in a cohort of patients with multi-drug refractory rheumatoid arthritis (RA) were published in The Lancet ...
Device reduced disease activity in 50% of patients who had failed multiple drug classes including Janus Kinase Inhibitors (JAKi) SetPoint Medical, Inc. today announced that data from a first-in-human pilot trial that evaluated its proprietary Vagus Nerve Stimulation (VNS) microregulator in a cohort of patients with multi-drug refractory rheumatoid arthritis (RA) were published in The Lancet ...
SetPoint Medical, a clinical-stage bioelectronic medicine company developing therapy for chronic autoimmune diseases, today announced that it has received Investigational Device Exemption (IDE) approval from the U.S. Food and Drug Administration (FDA) to study its proprietary bioelectronic platform in patients with rheumatoid arthritis (RA). The multicenter, double-blind, randomized, sham ...
SetPoint Medical, a clinical-stage bioelectronic medicine company developing therapy for chronic autoimmune diseases, today announced that Murthy Simhambhatla, Ph.D., President and Chief Executive Officer, is scheduled to present at the 13th annual Canaccord Genuity Medical Technologies & Diagnostics Forum, being held November 21, 2019 in New York, New York. Event: Canaccord Genuity ...
SetPoint Medical, a clinical-stage bioelectronic medicine company developing therapy for chronic autoimmune diseases, today announced that Murthy Simhambhatla, Ph.D., President and Chief Executive Officer, is scheduled to present at the 13th annual Canaccord Genuity Medical Technologies & Diagnostics Forum, being held November 21, 2019 in New York, New York. Event: Canaccord Genuity ...
SetPoint Medical, a clinical-stage bioelectronic medicine company developing therapy for chronic autoimmune diseases, today announced that results from its U.S. pilot Investigational Device Exemption (IDE) study in rheumatoid arthritis (RA) have been accepted for oral presentation at the American College of Rheumatology (ACR) Annual Meeting, being held November 8-13, 2019 in Atlanta, GA. The ...
Findings from a new study published today in Pediatric Research show that feeding activated Bifidobacterium infantis (B. infantis) EVC001 to breastfed infants reduced markers of chronic intestinal inflammation by up to 98 percent during the first two months of life, which is a critical period of immune system development. The study was led by researchers from The University of California, Davis ...
Tissue Genesis, a leading developer of cell therapy processing systems, announced today that an initial group of patients was successfully treated in the first clinical application of its Icellator® X technology at the Okyanos Center for Regenerative Medicine in Freeport, Bahamas. The new fully enclosed and automated system generated a higher yield of stem cells from adipose (fat) tissue than ...
Abcuro, a leading biotechnology company focused on immunology therapeutics, announced the completion of a $8M Series A financing round. Partners Innovation Fund, Kaitai Capital, and ShangPharma Innovation all contributed to the round. The proceeds from this financing will be used to advance the preclinical development of Abcuro’s programs in autoimmunity and immuno-oncology. Abcuro is ...
U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today announced the release of USRM Chief Science Officer Dr. Kristin Comella’s interview with Ben Pakulski — a world bodybuilding expert who last year received autologous stem cell therapy that successfully treated torn muscles. ...